Minyoung Kevin Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minyoung Kevin Kim has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Sang-Won Lee
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
6 shared publications - Yong-Beom Park
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
6 shared publications - Jason Jungsik Song
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
5 shared publications - Hyeok Choi
Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
3 shared publications - Paul L. Bollyky
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA
3 shared publications Carlos E. Milla
Center for Excellence in Pulmonary Biology, Department of Pediatrics, Stanford University, Stanford, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (5)
Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches
Bacteriophage (phage) therapy has emerged as a promising solution to combat the growing crisis of multidrug-resistant (MDR) infections. There are several international centers actively engaged in implementation of phage therapy, and recent case series have reported encouraging success rates in patients receiving personalized, compassionate phage therapy for difficult-to-treat infections. Nonetheless, substantial hurdles remain in the way of more widespread adoption and more consistent success. This Review offers a comprehensive overview of current phage therapy technologies and therapeutic approaches. We first delineate the common steps in phage therapy development, from phage bank establishment to clinical administration, and examine the spectrum of therapeutic approaches, from personalized to fixed phage cocktails. Using the framework of a conventional drug development pipeline, we then identify critical knowledge gaps in areas such as cocktail design, formulation, pharmacology, and clinical trial design. We conclude that, while phage therapy holds promise, a structured drug development pipeline and sustained government support are crucial for widespread adoption of phage therapy for MDR infections.
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (5)
Top Cited PapersOpen AccessBacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches
Bacteriophage (phage) therapy has emerged as a promising solution to combat the growing crisis of multidrug-resistant (MDR) infections. There are several international centers actively engaged in implementation of phage therapy, and recent case series have reported encouraging success rates in patients receiving personalized, compassionate phage therapy for difficult-to-treat infections. Nonetheless, substantial hurdles remain in the way of more widespread adoption and more consistent success. This Review offers a comprehensive overview of current phage therapy technologies and therapeutic approaches. We first delineate the common steps in phage therapy development, from phage bank establishment to clinical administration, and examine the spectrum of therapeutic approaches, from personalized to fixed phage cocktails. Using the framework of a conventional drug development pipeline, we then identify critical knowledge gaps in areas such as cocktail design, formulation, pharmacology, and clinical trial design. We conclude that, while phage therapy holds promise, a structured drug development pipeline and sustained government support are crucial for widespread adoption of phage therapy for MDR infections.
- Top Cited PapersOpen Access
- 28 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application is mainly limited to personalized therapy due to the narrow host range of individual phages. While phage cocktails targeting all possible bacterial receptors could theoretically confer broad coverage, the extensive diversity of bacteria and the complexity of phage-phage interactions render this approach challenging. Here, using screening protocols for identifying “complementarity groups” of phages using non-redundant receptors, we generate effective, broad-range phage cocktails that prevent the emergence of bacterial resistance. We also discover characteristic interactions between phage complementarity groups and particular antibiotic classes, facilitating the prediction of phage-antibiotic as well as phage-phage interactions. Using this strategy, we create three phage-antibiotic cocktails, each demonstrating efficacy against ≥96% of 153 Pseudomonas aeruginosa clinical isolates, including biofilm cultures, and demonstrate comparable efficacy in an in vivo wound infection model. We similarly develop effective Staphylococcus aureus phage-antibiotic cocktails and demonstrate their utility of combined cocktails against polymicrobial (mixed P. aeruginosa/S. aureus) cultures, highlighting the broad applicability of this approach. These studies establish a blueprint for the development of effective, broad-spectrum phage-antibiotic cocktails, paving the way for off-the-shelf phage-based therapeutics to combat multidrug-resistant bacterial infections.
- 28 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Top Cited PapersOpen AccessA blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application is mainly limited to personalized therapy due to the narrow host range of individual phages. While phage cocktails targeting all possible bacterial receptors could theoretically confer broad coverage, the extensive diversity of bacteria and the complexity of phage-phage interactions render this approach challenging. Here, using screening protocols for identifying “complementarity groups” of phages using non-redundant receptors, we generate effective, broad-range phage cocktails that prevent the emergence of bacterial resistance. We also discover characteristic interactions between phage complementarity groups and particular antibiotic classes, facilitating the prediction of phage-antibiotic as well as phage-phage interactions. Using this strategy, we create three phage-antibiotic cocktails, each demonstrating efficacy against ≥96% of 153 Pseudomonas aeruginosa clinical isolates, including biofilm cultures, and demonstrate comparable efficacy in an in vivo wound infection model. We similarly develop effective Staphylococcus aureus phage-antibiotic cocktails and demonstrate their utility of combined cocktails against polymicrobial (mixed P. aeruginosa/S. aureus) cultures, highlighting the broad applicability of this approach. These studies establish a blueprint for the development of effective, broad-spectrum phage-antibiotic cocktails, paving the way for off-the-shelf phage-based therapeutics to combat multidrug-resistant bacterial infections.
- Open Access
A Blueprint for Broadly Effective Bacteriophage Therapy Against Bacterial Infections
Summary: Bacteriophage therapy is a tantalizing therapeutic option for anti-microbial resistant bacterial infections but is currently limited to personalized therapy due to the narrow host range of individual phages. Theoretically, cocktails incorporating numerous phages targeting all possible bacterial receptor specificities could confer broad host range. Practically, however, extensive bacterial diversity and the complexity of phage-phage interactions precludes this approach. Here, using screening protocols for identifying “complementarity groups” of phages using non-redundant receptors, we generate effective, broad-range phage cocktails that prevent emergence of bacterial resistance. Further, phage complementarity groups have characteristic interactions with particular antibiotic classes, making it possible to predict phage-antibiotic as well as phage-phage interactions. Using this strategy, we generate three phage-antibiotic cocktails, each effective against >96% of 153 Pseudomonas aeruginosa clinical isolates, including when used in biofilm cultures and wound infections in vivo . We similarly develop effective Staphylococcus aureus phage-antibiotic cocktails and demonstrate the utility of combined cocktails against polymicrobial (mixed P. aeruginosa/S. aureus ) cultures, highlighting the broad applicability of this approach. These studies establish a blueprint for effective, broad-spectrum phage therapy cocktails and enable off-the-shelf phage-based therapeutics for antimicrobial-resistant bacterial infections.
Open AccessA Blueprint for Broadly Effective Bacteriophage Therapy Against Bacterial Infections
Summary: Bacteriophage therapy is a tantalizing therapeutic option for anti-microbial resistant bacterial infections but is currently limited to personalized therapy due to the narrow host range of individual phages. Theoretically, cocktails incorporating numerous phages targeting all possible bacterial receptor specificities could confer broad host range. Practically, however, extensive bacterial diversity and the complexity of phage-phage interactions precludes this approach. Here, using screening protocols for identifying “complementarity groups” of phages using non-redundant receptors, we generate effective, broad-range phage cocktails that prevent emergence of bacterial resistance. Further, phage complementarity groups have characteristic interactions with particular antibiotic classes, making it possible to predict phage-antibiotic as well as phage-phage interactions. Using this strategy, we generate three phage-antibiotic cocktails, each effective against >96% of 153 Pseudomonas aeruginosa clinical isolates, including when used in biofilm cultures and wound infections in vivo . We similarly develop effective Staphylococcus aureus phage-antibiotic cocktails and demonstrate the utility of combined cocktails against polymicrobial (mixed P. aeruginosa/S. aureus ) cultures, highlighting the broad applicability of this approach. These studies establish a blueprint for effective, broad-spectrum phage therapy cocktails and enable off-the-shelf phage-based therapeutics for antimicrobial-resistant bacterial infections.
- 8 November 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (3) , 773-781
A retrospective analysis of antineutrophil cytoplasmic antibody-associated vasculitis aiming for an equation prediction end-stage renal disease
We provided a predictable method that measures the risk of progression to end-stage renal disease (ESRD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by using a few routine serum markers of kidney functions at diagnosis. In a retrospective cohort study, the medical records of 254 AAV patients were reviewed. We derived a novel equation for the prediction of the progression to ESRD using variables with a P-value < 0.1 in the multivariable Cox hazard model analysis. We assigned a weight to each variable according to the slopes like a coefficient of a linear equation. The median age of the AAV patients was 59 years and 42 AAV patients progressed to ESRD. In the multivariable Cox analysis using variables with significance in the univariable analysis, MPO-ANCA (or P-ANCA) positivity, blood urea nitrogen, serum creatinine, and serum albumin tended to be associated with the progression to ESRD (P-value < 0.1). We develop an Equation for predicting ESRD in AAV (EPEA) using those variables with the slope of each one. When the cut-off of EPEA was set as −0.094, AAV patients with EPEA ≥ −0.094 had a significantly higher risk of progression to ESRD than those with EPEA < −0.094 (RR, 39.622). AAV patients with EPEA ≥ −0.094 exhibited a significantly lower ESRD-free survival rate than those with EPEA < −0.094. We provided a method to obtain EPEA and demonstrated its predictive potential for ESRD in immunosuppressive drug-naïve AAV patients. Key points • A novel equation for the prediction of the progression to ESRD was developed using variables with a P-value < 0.1 in the multivariable Cox hazard model analysis. A weight was assigned to each variable according to the slopes like a coefficient of a linear equation. • An optimal cut-off of EPEA for progression to ESRD was obtained using the receiver operator characteristic (ROC) curve analysis. • AAV patients with EPEA more than the cut-off had a significantly higher risk of progression to ESRD than those without (RR, 39.622). • AAV patients with EPEA more than the cut-off exhibited a significantly lower ESRD-free survival rate than those without.
- 8 November 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (3) , 773-781
A retrospective analysis of antineutrophil cytoplasmic antibody-associated vasculitis aiming for an equation prediction end-stage renal disease
We provided a predictable method that measures the risk of progression to end-stage renal disease (ESRD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by using a few routine serum markers of kidney functions at diagnosis. In a retrospective cohort study, the medical records of 254 AAV patients were reviewed. We derived a novel equation for the prediction of the progression to ESRD using variables with a P-value < 0.1 in the multivariable Cox hazard model analysis. We assigned a weight to each variable according to the slopes like a coefficient of a linear equation. The median age of the AAV patients was 59 years and 42 AAV patients progressed to ESRD. In the multivariable Cox analysis using variables with significance in the univariable analysis, MPO-ANCA (or P-ANCA) positivity, blood urea nitrogen, serum creatinine, and serum albumin tended to be associated with the progression to ESRD (P-value < 0.1). We develop an Equation for predicting ESRD in AAV (EPEA) using those variables with the slope of each one. When the cut-off of EPEA was set as −0.094, AAV patients with EPEA ≥ −0.094 had a significantly higher risk of progression to ESRD than those with EPEA < −0.094 (RR, 39.622). AAV patients with EPEA ≥ −0.094 exhibited a significantly lower ESRD-free survival rate than those with EPEA < −0.094. We provided a method to obtain EPEA and demonstrated its predictive potential for ESRD in immunosuppressive drug-naïve AAV patients. Key points • A novel equation for the prediction of the progression to ESRD was developed using variables with a P-value < 0.1 in the multivariable Cox hazard model analysis. A weight was assigned to each variable according to the slopes like a coefficient of a linear equation. • An optimal cut-off of EPEA for progression to ESRD was obtained using the receiver operator characteristic (ROC) curve analysis. • AAV patients with EPEA more than the cut-off had a significantly higher risk of progression to ESRD than those without (RR, 39.622). • AAV patients with EPEA more than the cut-off exhibited a significantly lower ESRD-free survival rate than those without.
- Open Access
- 1 January 2021
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 62 (2) , 149-158
Antineutrophil Cytoplasmic Antibody Positivity Is Associated with Vascular Involvement in Behçet's Disease
Kim MK, et al. Yonsei Med J. 2021 Feb;62(2):149-158. https://doi.org/10.3349/ymj.2021.62.2.149
- 1 January 2021
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 62 (2) , 149-158
Open AccessAntineutrophil Cytoplasmic Antibody Positivity Is Associated with Vascular Involvement in Behçet's Disease
Kim MK, et al. Yonsei Med J. 2021 Feb;62(2):149-158. https://doi.org/10.3349/ymj.2021.62.2.149
- Open Access
- 1 January 2020
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 61 (8) , 712-719
Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
Kwon HC, et al. Yonsei Med J. 2020 Aug;61(8):712-719. https://doi.org/10.3349/ymj.2020.61.8.712
- 1 January 2020
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 61 (8) , 712-719
Open AccessRituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
Kwon HC, et al. Yonsei Med J. 2020 Aug;61(8):712-719. https://doi.org/10.3349/ymj.2020.61.8.712
- 12 November 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (7) , 1063-1070
Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome?
We investigated the clinical implication of ANCA positivity at diagnosis on the poor outcomes in patients with Sjögren’s syndrome. The medical records of 606 Korean patients with Sjögren’s syndrome were retrospectively reviewed. The results of perinuclear (P)-ANCA, myeloperoxidase (MPO)-ANCA, cytoplasmic (C)-ANCA, and proteinase 3 (PR3)-ANCA were collected and the frequencies of all-cause mortality, interstitial lung disease (ILD), end-stage renal disease (ESRD), and lymphoma were assessed as the poor outcomes of Sjögren’s syndrome. Comparison of the cumulative patient survivals between the two groups was analysed by the Kaplan–Meier survival analysis. Of the 606 patients, ANCA was detected in 10.2% of Sjögren’s syndrome patients without AAV. Twenty-one patients (3.5%) died, 99 patients (16.3%) suffered from ILD, and 8 patients had ESRD. Lymphoma occurred in 5 patients (0.8%) during 37.5 months. Sjögren’s syndrome patients with ANCA positivity exhibited a lower cumulative ILD-free survival rate than those with ANCA negativity (P = 0.001). Sjögren’s syndrome patients with P-ANCA positivity and those with MPO-ANCA (or P-ANCA) positivity showed a lower cumulative ILD-free survival rate than those without (P = 0.012 and P < 0.001). Also, Sjögren’s syndrome patients with P-ANCA positivity exhibited a lower cumulative ESRD-free survival rate than those without (P = 0.043). ANCA positivity was associated with neither all-cause mortality nor lymphoma in Sjögren’s syndrome patients. ANCA positivity and MPO-ANCA (or P-ANCA) positivity at diagnosis was associated with the development of ILD during follow-up in patients with Sjögren’s syndrome.
- 12 November 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (7) , 1063-1070
Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome?
We investigated the clinical implication of ANCA positivity at diagnosis on the poor outcomes in patients with Sjögren’s syndrome. The medical records of 606 Korean patients with Sjögren’s syndrome were retrospectively reviewed. The results of perinuclear (P)-ANCA, myeloperoxidase (MPO)-ANCA, cytoplasmic (C)-ANCA, and proteinase 3 (PR3)-ANCA were collected and the frequencies of all-cause mortality, interstitial lung disease (ILD), end-stage renal disease (ESRD), and lymphoma were assessed as the poor outcomes of Sjögren’s syndrome. Comparison of the cumulative patient survivals between the two groups was analysed by the Kaplan–Meier survival analysis. Of the 606 patients, ANCA was detected in 10.2% of Sjögren’s syndrome patients without AAV. Twenty-one patients (3.5%) died, 99 patients (16.3%) suffered from ILD, and 8 patients had ESRD. Lymphoma occurred in 5 patients (0.8%) during 37.5 months. Sjögren’s syndrome patients with ANCA positivity exhibited a lower cumulative ILD-free survival rate than those with ANCA negativity (P = 0.001). Sjögren’s syndrome patients with P-ANCA positivity and those with MPO-ANCA (or P-ANCA) positivity showed a lower cumulative ILD-free survival rate than those without (P = 0.012 and P < 0.001). Also, Sjögren’s syndrome patients with P-ANCA positivity exhibited a lower cumulative ESRD-free survival rate than those without (P = 0.043). ANCA positivity was associated with neither all-cause mortality nor lymphoma in Sjögren’s syndrome patients. ANCA positivity and MPO-ANCA (or P-ANCA) positivity at diagnosis was associated with the development of ILD during follow-up in patients with Sjögren’s syndrome.
- Open Access
- 22 August 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (1) , e23022
Multivariable index for assessing the activity and predicting all‐cause mortality in antineutrophil cytoplasmic antibody‐associated vasculitis
Background: So far, there has been no tool to estimate activity at diagnosis and predict all‐cause mortality in patients with ANCA‐associated vasculitis (AAV). Hence, we determined the initial predictors of them in patients with AAV. Methods: We retrospectively reviewed the medical records of 182 patients with AAV. Severe AAV was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 16. The cutoffs were extrapolated by the receiver operator characteristic (ROC) curve. The odds ratio (OR) and the relative risk (RR) were assessed using the multivariable logistic regression analysis and the chi‐square test, respectively. Results: In the comparison analysis, patients with severe AAV exhibited the higher neutrophil and platelet counts, creatinine, erythrocyte sedimentation rate and C‐reactive protein, and the lower lymphocyte count, hemoglobin, and serum albumin than those without. In the multivariable logistic regression analysis, creatinine ≥ 0.9 mg/dL (OR 2.264), lymphocyte count ≤ 1430.0/mm 3 (OR 1.856), and hemoglobin ≤ 10.8 g/dL (OR 2.085) were associated with severe AAV. We developed a new equation of a multivariable index for AAV (MVIA) = 0.6 × (Lymphocyte count ≤ 1430.0/mm 3 ) + 0.7 × (Hemoglobin ≤ 10.8 g/dL) + 0.8 × (Creatinine ≥ 0.9 mg/dL). The optimal cutoff of MVIA for severe AAV was set as 1.35. Severe AAV was identified more frequently in patients with MVIA at diagnosis ≥1.35 than those without (RR 4.432). Patients with MVIA at diagnosis ≥1.35 exhibited the lower cumulative patient survival rate than those without. Conclusion: Multivariable index for AAV could assess the cross‐sectional activity and predict all‐cause mortality in patients with AAV.
- 22 August 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (1) , e23022
Open AccessMultivariable index for assessing the activity and predicting all‐cause mortality in antineutrophil cytoplasmic antibody‐associated vasculitis
Background: So far, there has been no tool to estimate activity at diagnosis and predict all‐cause mortality in patients with ANCA‐associated vasculitis (AAV). Hence, we determined the initial predictors of them in patients with AAV. Methods: We retrospectively reviewed the medical records of 182 patients with AAV. Severe AAV was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 16. The cutoffs were extrapolated by the receiver operator characteristic (ROC) curve. The odds ratio (OR) and the relative risk (RR) were assessed using the multivariable logistic regression analysis and the chi‐square test, respectively. Results: In the comparison analysis, patients with severe AAV exhibited the higher neutrophil and platelet counts, creatinine, erythrocyte sedimentation rate and C‐reactive protein, and the lower lymphocyte count, hemoglobin, and serum albumin than those without. In the multivariable logistic regression analysis, creatinine ≥ 0.9 mg/dL (OR 2.264), lymphocyte count ≤ 1430.0/mm 3 (OR 1.856), and hemoglobin ≤ 10.8 g/dL (OR 2.085) were associated with severe AAV. We developed a new equation of a multivariable index for AAV (MVIA) = 0.6 × (Lymphocyte count ≤ 1430.0/mm 3 ) + 0.7 × (Hemoglobin ≤ 10.8 g/dL) + 0.8 × (Creatinine ≥ 0.9 mg/dL). The optimal cutoff of MVIA for severe AAV was set as 1.35. Severe AAV was identified more frequently in patients with MVIA at diagnosis ≥1.35 than those without (RR 4.432). Patients with MVIA at diagnosis ≥1.35 exhibited the lower cumulative patient survival rate than those without. Conclusion: Multivariable index for AAV could assess the cross‐sectional activity and predict all‐cause mortality in patients with AAV.
- 1 August 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (11) , 1927-1936
Clinical significance of ANCA positivity in patients with IgA vasculitis: a retrospective monocentric study
We assessed the detection rate of antineutrophil cytoplasmic antibody (ANCA) and investigated the clinical significance of ANCA positivity at diagnosis in patients with IgA vasculitis (Henoch-Schönlein purpura). We retrospectively reviewed their medical records of 86 IgA vasculitis patients. We divided IgA vasculitis patients based on ANCA positivity and compared variables at diagnosis and poor outcomes and medication during follow-up between the two groups. All-cause mortality, relapse, chronic kidney disease (CKD) (stage 3–5) and end-stage renal disease (ESRD) were defined as poor outcomes. We assessed the renal histological features based on the International Study of Kidney Disease in Children (ISKDC) classification and Oxford classification. Comparison of cumulative survivals was analysed by the Kaplan–Meier survival analysis. Five of 86 IgA vasculitis patients (5.8%) had ANCA and all ANCA-positive patients had myeloperoxidase (MPO)-ANCA. IgA vasculitis patients with ANCA exhibited pulmonary and nervous involvement of IgA vasculitis more frequently than those without. There was no significant difference in renal involvement between the two groups. There were no significant differences in renal histological features and poor outcomes related to renal function between IgA vasculitis patients with and without ANCA. In addition, 5 IgA vasculitis patients did not meet the classification criteria for ANCA-associated vasculitis (AAV). Particularly, there were no significant differences in CKD and ESRD-free survival rates between IgA vasculitis patients with and without ANCA. 5.8% of IgA vasculitis patients had MPO-ANCA and poor outcomes of IgA vasculitis were not affected by the presence of ANCA.
- 1 August 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (11) , 1927-1936
Clinical significance of ANCA positivity in patients with IgA vasculitis: a retrospective monocentric study
We assessed the detection rate of antineutrophil cytoplasmic antibody (ANCA) and investigated the clinical significance of ANCA positivity at diagnosis in patients with IgA vasculitis (Henoch-Schönlein purpura). We retrospectively reviewed their medical records of 86 IgA vasculitis patients. We divided IgA vasculitis patients based on ANCA positivity and compared variables at diagnosis and poor outcomes and medication during follow-up between the two groups. All-cause mortality, relapse, chronic kidney disease (CKD) (stage 3–5) and end-stage renal disease (ESRD) were defined as poor outcomes. We assessed the renal histological features based on the International Study of Kidney Disease in Children (ISKDC) classification and Oxford classification. Comparison of cumulative survivals was analysed by the Kaplan–Meier survival analysis. Five of 86 IgA vasculitis patients (5.8%) had ANCA and all ANCA-positive patients had myeloperoxidase (MPO)-ANCA. IgA vasculitis patients with ANCA exhibited pulmonary and nervous involvement of IgA vasculitis more frequently than those without. There was no significant difference in renal involvement between the two groups. There were no significant differences in renal histological features and poor outcomes related to renal function between IgA vasculitis patients with and without ANCA. In addition, 5 IgA vasculitis patients did not meet the classification criteria for ANCA-associated vasculitis (AAV). Particularly, there were no significant differences in CKD and ESRD-free survival rates between IgA vasculitis patients with and without ANCA. 5.8% of IgA vasculitis patients had MPO-ANCA and poor outcomes of IgA vasculitis were not affected by the presence of ANCA.